Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging.
Contrast-enhanced magnetic resonance (MR) imaging was used to detect and quantify the extent of myocardial injury after a brief coronary occlusion and reperfusion in response to verapamil treatment in a rat model of left ventricular hypertrophy (LVH). Two groups of rats were prepared by banding the abdominal aorta for 7 to 8 weeks to produce LVH. Group 1 (n = 13) received oral verapamil for 3 days, whereas group 2 (n = 13) received no therapy. Before MR examination was performed, each rat was subjected to 25 min of coronary artery occlusion followed by 1 hour of reperfusion. T1-weighted spin echo images were acquired before and after 0.3 mmol/kg gadoteridol was injected. Three images were acquired at contiguous levels of the LV and used to estimate the size of the myocardial injury. The size of the infarcted region was demarcated at postmortem examination by using triphenyltetrazolium chloride dye (TTC). Before contrast medium was administered, no significant difference in signal intensity was seen between nonischemic and reperfused ischemically injured myocardium. After gadoteridol was injected, a hyperintense zone indicative of myocardial injury was observed in 8 of 13 rats treated with verapamil and in all untreated animals. The size of the injury was significantly larger in untreated hearts than in hearts treated with verapamil as defined on MR images (25% +/- 5% vs 18% +/- 5%, p < 0.05) and TTC staining (12% +/- 4% and 4% +/- 1%, p < 0.05). Good correlation (r = 0.91) was found between the two measurements. No significant difference in the size of jeopardy area was seen between the two groups as (defined by blue dye infusion). In conclusion, contrast-enhanced MR imaging is a suitable technique to evaluate the effects of therapies applied to reduce myocardial injury. Verapamil can cause reduction in the extent of ischemic injury after reperfusion of hypertrophied myocardium.
Lauerma
K
K
Department of Radiology, University of California, San Francisco 94143-0628, USA.
Saeed
M
M
Wendland
M F
MF
Derugin
N
N
Yu
K K
KK
Higgins
C B
CB
D000818:Animals; D001012:Aorta, Abdominal / Q000601:surgery; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D004396:Coloring Agents; D003287:Contrast Media; D004195:Disease Models, Animal; D005682:Gadolinium; D006571:Heterocyclic Compounds; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology*; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D009942:Organometallic Compounds; D051381:Rats; D017207:Rats, Sprague-Dawley; D013778:Tetrazolium Salts; D014700:Verapamil / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D004396:Coloring Agents; D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; D013778:Tetrazolium Salts; C062402:gadoteridol; C009591:triphenyltetrazolium; D005682:Gadolinium; D014700:Verapamil